Home Infusors for Analgesia After Foot Surgery
Recruitment status was: Enrolling by invitation
|Hallux Valgus||Procedure: elastomeric pump with reservoir of 500 ml, infusion rate of 8 ml/h Procedure: elastomeric pump with reservoir of 275 ml, infusion rate of 5 ml/h||Phase 4|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Use of Home Pumps for Analgesia After Ambulatory Foot Surgery - Comparison of Two Infusion Rates - a Randomized, Double-Blind Study|
- worst pain [ Time Frame: first postoperative day ]
- Average pain [ Time Frame: 1st, 2nd and 3rd postoperative days ]
- Opioid consumption [ Time Frame: first, second and third postoperative days ]
- Side effects [ Time Frame: 1st, 2nd and 3rd postoperative days ]
|Study Start Date:||September 2008|
|Estimated Study Completion Date:||December 2010|
|Estimated Primary Completion Date:||December 2009 (Final data collection date for primary outcome measure)|
Group A patients will receive perisciatic continuous infusion of ropivacaine 2 mg/ml through an elastomeric pump (Baxter, Deerfield, IL, USA)) 8 ml/h (reservoir of 500 ml)as postoperative analgesia.
Procedure: elastomeric pump with reservoir of 500 ml, infusion rate of 8 ml/h
Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 500 ml reservoir and infusion rate of 8 ml/h)
Active Comparator: B
Group B patients will receive standard treatment: continuous perisciatic infusion of 2 mg/ml ropivacaine 5 ml/t (Baxter infusor with 275 ml reservoir)
Procedure: elastomeric pump with reservoir of 275 ml, infusion rate of 5 ml/h
Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 275 ml reservoir and infusion rate of 5ml/h)
Use of home pumps for analgesia after ambulatory foot surgery - comparison of two infusion rates SUMMARY in English
The purpose of this double blind, randomized study is to evaluate which rate and duration of infusion can be recommended for continuous perisciatic infusion of ropivacaine 2 mg/ml for analgesia after ambulatory foot surgery.
In the previous study (1) we showed that the continuous perisciatic infusion of 2 mg/ml ropivacaine 5 ml/h for 55 hours provided better analgesia than placebo after ambulatory foot surgery. Similar results are reported by Singelyn (2), Ilfeld (3) and White (4). But, different pumps with different basal infusion rates were used in these studies. Singelyn used infusion rate of 7 ml/h for 48 hours, while Ilfeld used mechanical pump with adjustable infusion rate, starting with 8 ml/h and patient controlled analgesia (PCA) 2 ml/20 minutes for 2 postoperative days. In our and White's studies elastomeric pumps with reservoir of 500 ml and infusion rate of 5 ml/h were used in 55 hours. Capdevila (5) has shown that the patients prefer elastomeric pumps because they cause fewer problems. That is why it will be our choice as well.
The analgesic efficacy in our study was good as the patients in the treatment group had less pain and fewer sleep disturbances than in the placebo group. The question is whether higher infusion rate and longer duration would have an even better effect.
The aim of this study is to compare (in a double blind manner) two different regimens for continuous perisciatic nerve infusion of ropivacaine 2 mg/ml after ambulatory foot surgery:
- elastomeric pump with reservoir of 275 ml, infusion rate of 5 ml/h (duration 55 hours) and
- elastomeric pump with reservoir of 500 ml, infusion rate of 8 ml/h (duration 62 hours).
A randomized, double blind study with 40 ambulatory patients who will undergo foot or ankle surgery. These patients will be randomized to receive either regimen 1. (5 ml/h for 55 hours) or regimen 2. (8 ml/h for 62 hours). The randomization procedure: sequentially numbered, sealed, opaque envelopes that contain computer produced random numbers for treatment allocation. Blinding procedures: pre-numbered identical containers marked with "Test drug", date of production and infusion start/end will be provided by the registered nurse (SK). The patient and the acute pain nurse (EB), who will evaluate the effect of these two treatments, will be blinded.
On each of the 3 postoperative days the patients will be contacted by phone by the acute pain nurse and a standard questionnaire will be completed.
The primary effect variable is worst pain on the first postoperative day evaluated as VAS score.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00600899
|Frederiksberg, Denmark, 2000|
|Principal Investigator:||Dusanka Zaric, MD pHd||Ndr. Fasanvej 57 2000 Frederiksberg|